AstraZeneca PLC (AZN)vsPrecision Optics Corporation, Inc. Common stock (POCI)
AZN
AstraZeneca PLC
$169.51
-0.34%
HEALTHCARE · Cap: $263.78B
POCI
Precision Optics Corporation, Inc. Common stock
$4.34
-1.59%
HEALTHCARE · Cap: $47.51M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 194516% more annual revenue ($61.37B vs $31.53M). AZN leads profitability with a 17.0% profit margin vs -11.5%. AZN earns a higher WallStSmart Score of 62/100 (C+).
AZN
Buy62
out of 100
Grade: C+
POCI
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+13.1%
Fair Value
$194.96
Current Price
$169.51
$25.45 discount
Margin of Safety
-9.9%
Fair Value
$4.55
Current Price
$4.34
$0.21 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Revenue surging 42.0% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Moderate valuation
2.5% earnings growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -29.6% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.22 suggests the stock is reasonably priced for its growth.
Bull Case : POCI
The strongest argument for POCI centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 42.0% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.
Bear Case : POCI
The primary concerns for POCI are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a mature stock while POCI is a hypergrowth play — different risk/reward profiles.
POCI carries more volatility with a beta of 0.34 — expect wider price swings.
POCI is growing revenue faster at 42.0% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (62/100 vs 36/100), backed by strong 17.0% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Precision Optics Corporation, Inc. Common stock
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Precision Optics Corporation, Inc. designs, develops, manufactures, and sells specialized optical and lighting systems and related components primarily in the United States and the European Economic Area. The company is headquartered in Gardner, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?